2-氯-6-甲基苯肼 | 89187-46-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-6-甲基苯肼
• 中文别名: (2-氯-6-甲基苯基)肼
• 英文名称: 6-chloro-2-methylphenylhydrazine
• 英文别名: (2-Chloro-6-methylphenyl)hydrazine
• CAS: 89187-46-2
• 化学式: C₇H₉ClN₂
• 分子量: 156.615
• InChiKey: ZPGVNHBXCQUDKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲基苯肼 在 dipotassium peroxodisulfate 、 ferric alum 、 硫酸 作用下， 以 溶剂黄146 为溶剂， 反应 3.5h， 生成 di(6-chloro-2-methylphenyl)carbazone
  参考文献：
  名称：

  二（6-氯-2-甲基苯基）卡巴zone与镍（II）螯合物形成杂环氮碱的研究。

  摘要：

  通过磁化率，UV-VIS，IR和1H-NMR光谱法合成并表征了Ni（II）二（6-氯，2-甲基苯基）氨基甲酸Ni（II）加合物的形成。扭曲的方形平面Ni（II）螯合物与杂环氮碱形成加合物；分光光度法已用于研究单相氯仿中加合物的形成。双齿和不饱和单齿异核氮碱都分别形成化学计量比为1：1和1：2的六配位加合物（金属螯合物：碱）。但是，饱和氮碱形成化学计量比为1：1的五配位加合物。根据碱基的碱性和空间因素讨论了结果。

  DOI：

  10.1016/s1386-1425(00)00316-4

文献信息

• [EN] 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 1,5-DIHYDRO-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PDE9A POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009068617A1

  公开（公告）日：2009-06-04

  The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl and C1-C6-alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C1-C6-alkyI, C1-C6- alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C1-C6- alkylamino, halogen, C6-C10-arylcarbonylamino, C1-C6-alkylcarbonylamino, C1- C6-alkylaminocarbonyl. C1-C6-alkoxycarbonyl, C6-C10-arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C1-C6-alkylsulphonyl- amino, C1-C6-alkylsulphonyl and C1-C6-alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.

  该发明涉及新型取代吡唑吡嘧啶化合物。从化学角度来看，这些化合物的特征由一般式（I）表示：其中R1为苯基或吡啶基，其中任一取代为1到4个，优选为1到3个取代基X；X独立地选自C2-C6-烷基或C1-C6-烷氧基，其中C2-C6-烷基和C1-C6-烷氧基至少经过二卤化至全卤化处理，最好具有2到6个卤素取代基，卤素原子选自氟、氯和溴，最好为氟；R2为苯基或杂环烷基，其中苯基取代为1到3个基团，杂环烷基可选择性地取代为1到3个基团，每种基团独立地选自C1-C6-烷基、C1-C6-烷氧基、羟基羰基、氰基、三氟甲基、氨基、硝基、羟基、C1-C6-烷基氨基、卤素、C6-C10-芳基羰胺基、C1-C6-烷基羰胺基、C1-C6-烷氨基羰基、C1-C6-烷氧羰基、C6-C10-芳基氨基羰基、杂环烷基氨基羰基、杂环烷基羰胺基、C1-C6-烷基磺酰氨基、C1-C6-烷基磺酰基和C1-C6-烷基硫基；这些新化合物可用于制备药物，特别是用于改善患者的感知、注意力、学习和/或记忆的药物。
• Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
  申请人：Fukumoto Shoji

  公开号：US20090253687A1

  公开（公告）日：2009-10-08

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

  本发明涉及其中每个符号如规范所定义的化合物，该化合物具有优越的矿物质皮质激素受体拮抗作用，可作为预防或治疗高血压、心力衰竭等药物，包括具有融合杂环的化合物、其前药或其盐；以及预防或治疗高血压、心力衰竭等疾病的药剂。
• CRTH2 Receptor Ligands For Medicinal Uses
  申请人：Ulven Trond

  公开号：US20090099189A1

  公开（公告）日：2009-04-16

  Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A 1 , is hydrogen or methyl; ring Ar 1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA 1 CHO— and L2 are linked to adjacent ring atoms; rings Are 2 , Ar 3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

  式(I)的化合物可用于治疗对CRTH2受体活性调节敏感的疾病，例如哮喘、鼻炎、过敏性气道综合症和过敏性鼻支气管炎，其中A代表羧基—COON或羧基生物同位素；A1为氢或甲基；环Ar1是一个可选取代的苯环5-或6-成员的单环杂环，其中AA1CHO—和L2与相邻的环原子连接；环Are2，Ar3各自独立地表示一个苯环或5-或6-成员的单环杂环，或由一个5-或6-成员的碳环或杂环组成的双环系统，该环或环系统被苯并或与一个5-或6-成员的单环杂环融合，该环或环系统是可选取代的；t为0或1；L2和L3是如描述中所定义的连接基团。
• CRTH2 receptor ligands for medicinal uses
  申请人：Ulven Trond

  公开号：US20110269763A1

  公开（公告）日：2011-11-03

  Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis: wherein A represents a carboxyl group —COOH, or a carboxyl bioisostere; A 1 is hydrogen or methyl; ring Ar 1 is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which AA 1 CHO— and L2 are linked to adjacent ring atoms; rings Ar 2 , Ar 3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

  式(I)的化合物可用于治疗对CRTH2受体活性调节敏感的疾病，例如哮喘、鼻炎、过敏性气道综合症和过敏性鼻支气管炎：其中A代表羧基—COOH或羧基生物同位素；A1为氢或甲基；环Ar1为可选取代的苯环或5-或6-成员的单环杂环，其中AA1CHO—和L2连接到相邻的环原子上；环Ar2、Ar3各自独立地表示苯环或5-或6-成员的单环杂环，或由5-或6-成员的碳环或杂环组成的双环系统，该环或环系统是苯并或与5-或6-成员的单环杂环融合，该环或环系统是可选的取代；t为0或1；L2和L3是如描述中定义的连接基。
• CRTH2 Receptor Ligands for Medical Use
  申请人：7TM Pharma A/S

  公开号：EP2336113A1

  公开（公告）日：2011-06-22

  4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyl acetic acid is useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

  4-溴-2-[1-（2,6-二氯苯基）-1H-吡唑-4-甲酰基]苯氧乙酸可用于治疗对调节 CRTH2 受体活性有反应的疾病，如哮喘、鼻炎、过敏性气道综合征和过敏性鼻支气管炎。